Britain and America have signed a major trade agreement that will preserve zero import taxes on British pharmaceutical shipments entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the public health system. This commitment guarantees that import taxes on these vital exports will be held at zero for a duration of the next three years.
This agreement comes after previous threats to significantly raise tariffs on patented pharmaceutical imports, with potential rates discussed as high as 100%.
"This arrangement between the Britain strengthens the international landscape for cutting-edge drugs and introduces long-overdue fairness to transatlantic pharmaceutical trade," a release noted.
Economic Importance
Drugs are one of the Britain's most significant goods shipped to the America, which is by far the biggest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of the third quarter, the UK shipped medicines worth £11.1bn to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be restricted at 15%. Last year, rebates topped twenty percent.
Industry Background
The deal comes amid a ongoing row between the sector and the British authorities over medicine costs and NHS adoption.
These tensions were exacerbated by claims that American patients were paying several times more for the identical medicines than people in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or cancelled, while substantial investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
